New hope for hepatitis b patients when standard drugs fail
NCT ID NCT07090759
Summary
This large Phase 3 trial is testing whether adding a new drug called Neracorvir (GST-HG141) helps patients with chronic hepatitis B who still have detectable virus despite taking standard antiviral pills. The study will enroll over 500 adults who haven't responded well to their current treatment. Participants will be randomly assigned to receive either the new add-on drug or a placebo, in addition to their regular medication, to see if it better controls the virus.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shulan(Hangzhou) Hospital
RECRUITINGHangzhou, Zhejiang, 310011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.